Ignite Creation Date:
2024-05-06 @ 4:07 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04882072
Status:
TERMINATED
Last Update Posted:
2023-08-01
First Post:
2021-05-10
Brief Title:
A Study of Ustekinumab in Participants With Takayasu Arteritis TAK
Sponsor:
Janssen Pharmaceutical KK
Organization:
Janssen Pharmaceutical KK
Study Overview
Official Title:
A Phase 3 Multicenter Randomized Double-blind Placebo-controlled Parallel-group Study of Ustekinumab in Participants With Takayasu Arteritis
Status:
TERMINATED
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Due to difficulties in enrollment and ongoing feasibility issues
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy of ustekinumab compared to placebo in combination with oral glucocorticoid GC taper regimen in participants with relapsing Takayasu Arteritis TAK
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CNTO1275TAT3001 | OTHER | Janssen Pharmaceutical KK Japan | None |